Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 5/20 | 0.33 |
| ▸ | FLT4 | P35916 | 5/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287455 | 0.81 | KDR (0.55) | KDRFLT1FLT4FGFR1EGFR | |
| SCHEMBL4281050 | 0.78 | KDR (0.76) | KDRFLT1FLT4FGFR1 | |
| SCHEMBL4282322 | 0.72 | GCK (0.33) | KDRNPC1RAB9AKDM4C | |
| SCHEMBL4289465 | 0.71 | KDR (0.45) | KDRFGFR1EGFR | |
| SCHEMBL4283777 | 0.70 | KDR (0.40) | KDRFGFR1EGFR | |
| SCHEMBL4284980 | 0.69 | KDR (0.56) | KDRFGFR1 | |
| SCHEMBL4283669 | 0.68 | KDR (0.37) | KDRFGFR1EGFR | |
| SCHEMBL4278293 | 0.65 | KDR (0.55) | KDRFGFR1 | |
| SCHEMBL4771707 | 0.64 | KDR (0.42) | KDRFGFR1EGFR | |
| SCHEMBL4280702 | 0.64 | KDR (0.43) | KDRFGFR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | KDR 2/4885ICAM1 2418/4885SELE 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.